Transducer programs in active development.
Each program originates from FORCE-generated hypotheses and is being advanced through wet-lab validation toward IND-enabling studies.
FASN-Redirect
Fatty Acid Synthase / SCD1 Axis
NASH / Hepatic Steatosis
Redirects de novo lipogenesis away from triglyceride accumulation toward oxidative disposal via CPT1A-mediated fatty acid oxidation.
OxPhos-Tuner
Complex I / AMPK Axis
Obesity / Insulin Resistance
Tunes oxidative phosphorylation efficiency to increase basal metabolic rate and restore insulin sensitivity in adipose tissue.
Ceramide-Block
Sphingolipid Pathway / CerS6
Type 2 Diabetes
Blocks ceramide biosynthesis at the CerS6 node to prevent lipotoxicity-driven beta-cell dysfunction.
Mevalonate-Shunt
HMGCR / Prenylation Branch
Oncology (KRAS-mutant NSCLC)
Shunts mevalonate pathway flux away from cholesterol toward prenylation substrates to disrupt KRAS membrane localization.
All programs are preclinical. Confidence scores reflect computational prediction from FORCE analyses and are not validated clinical endpoints. Meteor Biosciences does not claim therapeutic efficacy for any pipeline program without published wet-lab validation data.
Interested in co-development?
We partner with pharma and biotech teams to advance transducer programs from FORCE-generated hypotheses to IND.